CPT
Camden Property Trust
stock NYSE

A medical FDA approved ASX only moves quickly when they have CPT codes (I believe this is the equivalent to Medicare item number) to claim reimbursement (E.g., 4DX, AYA, also recently FDA approved with CPT codes, no denovos), I think Paincheck has a long way to go. It's a long process for a denovo to start claiming reimbursement, which mean people can't claim it from their insurances, and we all know how expensive US healthcare it is, so there is limited access for the general population. That said, I don't know a lot about the type of product or how much demand there is for it. I might be wrong, but hoping for the best.

A Kind of General Overview
OneMedNet (NASDAQ: ONMD) operates a Real-World Data platform that provides access to healthcare data for life sciences, medical device companies, and research organizations. The company's iRWD platform provides access to more than 5 billion administrative claims and 131 million clinical exams across 1,750+ provider sites, spanning oncology, cardiology, and rare diseases.
Recent Palantir Partnership (October 6, 2025)
OneMedNet selected Palantir Technologies (NASDAQ: PLTR) to transform the healthcare AI and Real-World Data analytics marketplace under a multi-year agreement. Palantir's Artificial Intelligence Platform will provide the infrastructure for OneMedNet's iRWD near real-time AI powered provider network.
The stock surged 148% on the announcement. [Source: Parameter.io, October 2025]
Key Technical Benefits
The partnership enables faster data discovery with customer data inquiries fulfilled in minutes instead of days, accurate data delivery through custom cohorts, and conversational search powered by Palantir's AIP and LLMs. The platform integrates healthcare standards including SNOMED, HCPCS, ICD-10, and CPT codes to ensure interoperable data access.
Market Opportunity
Access to healthcare data remains a key barrier to unlocking the $868 billion market opportunity in AI-driven healthcare by 2030. [Source: Strategy&, PWC]
The company positions itself as infrastructure for healthcare AI development, providing anonymized, regulatory-grade clinical data to accelerate medical solution development.
Business Model Evolution
OneMedNet is transitioning toward subscription-based recurring revenue through Data License Agreements. In August 2025, they announced a partnership with Circle Cardiovascular Imaging providing access to their cardiac imaging database through a subscription model. [Source: Company press releases]
The company has expanded partnerships with top medical device companies under evergreen master services agreements, creating ongoing revenue streams rather than project-based work.
Bull Case for Continued Upside
1. Partnership Validation: Palantir's involvement validates the technology and business model. Palantir is selective with partnerships and this positions ONMD as legitimate infrastructure in the healthcare AI space.
2. Scalable Revenue Model: The shift to subscription-based Data License Agreements creates recurring revenue streams that command higher valuations than project-based consulting work.
3. Network Effects: With access to over 1,750 provider sites, OneMedNet's network creates a moat that becomes more valuable as more data is added.
4. Market Timing: Healthcare AI is rapidly expanding and companies need access to real-world clinical data to train models and validate products. ONMD provides critical infrastructure for this market.
5. Technical Advantages: Palantir's platform enables automation to improve efficiency and reduce costs, enabling scalable growth with improved margins.
6. Multiple Therapeutic Areas: The platform spans oncology, cardiology, and rare diseases, diversifying revenue opportunities across high-value therapeutic categories.

💡 Bullish Points (Why it’s a buy)
• Breakthrough tech: Fully implanted Acclaim® cochlear implant — could disrupt hearing market.
• Strong patents: 3 new global patents — protects future tech.
• Clinical progress: Early trials on track, no serious safety issues.
• Regulatory tailwinds: New CPT codes aid reimbursement.
• Debt cleared: ~$32M debt removed; $2.5M raised to fund growth.
• Tiny market cap: Valued like a penny stock — huge upside potential.
• Clean early safety data: Supports long-term FDA pathway.
📈 Why Bulls Love It
• Massive asymmetric upside — tiny price, huge potential.
• IP + first-mover edge in “fully implanted” market.
• Early data looks promising.
• Cleaned balance sheet = fresh start.
• Market still sleeping on it — classic underdog setup.
Im getting in tomorrow.
Not financial advice✅✅✅✅✅✅
Volume popppinngggg aswelll